Galmed Pharmaceuticals Ltd.
GLMD
$1.55
-$0.08-4.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 06/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | 48.45% | 48.45% | 53.10% |
| Total Depreciation and Amortization | -- | -- | 185.29% | 185.29% | -5.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -17.87% | -17.87% | -54.35% |
| Change in Net Operating Assets | -- | -- | -367.09% | -367.09% | 78.40% |
| Cash from Operations | -- | -- | 41.94% | 41.94% | 57.46% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -93.80% | -93.80% | -100.94% |
| Cash from Investing | -- | -- | -93.80% | -93.80% | -100.94% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 8,735.71% | 8,735.71% | 8,735.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 8,735.71% | 8,735.71% | 8,735.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | 185.67% | 185.67% | 90.04% |